Double-Filtration Plasmapheresis Plus Low-Dose Anti-thymocyte Globulin and Tacrolimus in Asian Living-Donor Kidney Transplantation With Donor-Specific Anti-HLA Antibody

Kantachuvesiri, Surasak; Ingsathit, Atiporn; Thammanichanond, Duangtawan; Choochaeam, Kunvadee; Sra-ium, Supasil; Kitiyakara, Chagriya; Nongnuch, Arkom; Sakulchairungrueng, Bundit; Worawichawong, Suchin

doi:10.1016/j.transproceed.2020.08.019

Cited by 4 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DFPP, a semi‐selective plasma purification, avoids the unnecessary loss of plasma proteins, reduces the need for liquid replacement and increases the efficiency of purification 9,10,23 . Previous studies proved that DFPP efficiently decreased the level of DSA of kidney transplantation patients, although hypotension occurred more frequently than PE 9,12,13,24 . Our results demonstrated that DFPP treatment can decrease the levels of DSA efficiently.…”

Section: Discussionsupporting

confidence: 54%

“…9,10,23 Previous studies proved that DFPP efficiently decreased the level of DSA of kidney transplantation patients, although hypotension occurred more frequently than PE. 9,12,13,24 Our results demonstrated that DFPP treatment can decrease the levels of DSA efficiently. The mean MFI values before and after treatment were 7505.88 ± 4424.38 and 2013.29 ± 4067.22 (p < 0.001) respectively.…”

Section: Discussionsupporting

confidence: 53%

“…Compared to PE, DFPP provides a more selective large‐molecule removal, reduced need for plasma and increases the efficiency of purification 9,10 . Some reports have shown that DFPP was effective in the treatment for many immune‐related diseases such as myasthenia gravis 11 and antibodies desensitization in organ transplantation such as kidney transplantation 12,13 . However, there are no studies with large number of patients in DSA desensitization effect and outcome of DFPP treatment for Haplo‐HSCT patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Double filtration plasmapheresis combined with rituximab for donor‐specific antibody desensitization in haploidentical haematopoietic stem cell transplantation

Liu,

Ji,

Zhu

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

SummaryDonor‐specific anti‐HLA antibodies (DSA) are a major cause of engraftment failure in patients receiving haploidentical haematopoietic stem cell transplantation (Haplo‐HSCT). Double filtration plasmapheresis (DFPP) avoids the unnecessary loss of plasma proteins and increases the efficiency of purification. To investigate the effectiveness of the desensitization protocol including DFPP and rituximab, we conducted a nested case–control study. Thirty‐three patients who had positive DSA were desensitized by the protocol and 99 patients with negative DSA were randomly matched as control. The median DSA mean fluorescence intensity values before and after DFPP treatment were 7505.88 ± 4424.38 versus 2013.29 ± 4067.22 (p < 0.001). All patients in DSA group achieved haematopoietic reconstitution and the median neutrophils and platelets engraftment times were 13 (10–21) and 13 (10–29) days respectively. Although the cumulative incidence of II–IV aGVHD (41.4% vs. 28.1%) and 3‐year moderate to severe cGVHD (16.8% vs. 7.2%) were higher in DSA cohort than in the control, no statistical significance was observed. The 3‐year non‐relapse mortality and the overall survival were 6.39% and 72.0%, respectively, in the DSA cohort, which were comparable to the negative control. In conclusion, DFPP and rituximab could be effectively used for desensitization and overcome the negative effects of DSA in Haplo‐HSCT.

show abstract

Section: Discussionsupporting

confidence: 54%

Section: Discussionsupporting

confidence: 53%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Double filtration plasmapheresis combined with rituximab for donor‐specific antibody desensitization in haploidentical haematopoietic stem cell transplantation

Liu,

Ji,

Zhu

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…It has long been recognized that immunosuppressant pharmacokinetics exhibit ethnicity-specific differences in bioavailability and dose-dependent systemic exposure. Recently, several studies reported a higher incidence of infectious complications in Asian kidney recipients with ATG induction which is the main reason why a physician is reluctant to use ATG as induction regimen [15][16][17]. Therefore, it is necessary to understand clinical outcomes and adverse events according to the dose of ATG in Asian patients.…”

Section: Introductionmentioning

confidence: 99%

A prospective, randomized, non-blinded, non-inferiority pilot study to assess the effect of low-dose anti-thymocyte globulin with low-dose tacrolimus and early steroid withdrawal on clinical outcomes in non-sensitized living-donor kidney recipients

et al. 2023

View full text Add to dashboard Cite

Background The optimal dose of anti-thymocyte globulin (ATG) as an induction regimen in Asian living-donor kidney recipients is unclear. Methods This is a pilot study in which 36 consecutive patients undergoing living-donor kidney transplantation were randomly assigned to receive either 4.5 mg/kg (n = 19) or 6.0 mg/kg (n = 17) of ATG; all patients had corticosteroid withdrawal within 7 days. The primary end point was a composite of biopsy-proven acute rejection, de novo donor-specific antibody formation, and graft failure. Results At 12 months post-transplant, biopsy-proven acute rejection was more common in the ATG4.5 group (21.1%) than in the ATG6.0 group (0%)(P = .048). Importantly, the rate of the composite end point was significantly higher in the ATG4.5 group (36.8% vs 0%)(P = .006). There were significant differences in neither the renal function nor adverse events between the two groups. One case of death-censored graft failure occurred in the ATG4.5 group and no mortality was observed overall. Compared with pre-transplantation, T cells, natural killer (NK) cells, and natural killer T (NKT) cells were significantly decreased in the first week post-transplantation except for B cells. Although T and NKT cells in both groups and NK cells in the ATG4.5 group had recovered to the pre-transplant levels, NK cells in the ATG6.0 group remained suppressed until six months post-transplant. Conclusions Compared with ATG 6.0 mg/kg, ATG 4.5 mg/kg with early corticosteroid withdrawal and low dose maintenance regimen was associated with higher rates of acute rejection in non-sensitized Asian living-donor kidney recipients. Trial registration ClinicalTrials.gov: NCT02447822.

show abstract

“…DFPP is used for the treatment of various pathologies, depending on the target substance to be eliminated (immunoglobulins, LDL‐cholesterol or fibrinogen and clotting factors in order to improve blood rheology and tissue perfusion) 1‐10 …”

Section: Introductionmentioning

confidence: 99%

How to improve clotting factors depletion in double‐filtration plasmapheresis

Bennani

Marlu

Terrec

et al. 2021

J of Clinical Apheresis

View full text Add to dashboard Cite

Background Double‐filtration plasmapheresis (DFPP), a selective therapeutic apheresis, can deplete pathogenic antibodies/substances, but also important coagulation factors. Aim To determine if the use of a separator filter with different characteristics (CascadefloEC‐50 W) as compared to the reference filter (PlasmafloOP‐08 W) is as efficient in terms of immunoglobulin loss, but can reduce coagulation factor losses and have similar tolerability. Patients/Methods This is a single‐center prospective study including 14 patients divided into two groups (7 each): that is, group1 = CascadefloEC‐50 W and group2 = PlasmafloOP‐08 W. We measured immunoglobulins, lipid profiles, blood‐cell counts, hemostasis (prothrombin time, activated partial thromboplastin time), coagulation factors, and natural anticoagulants at before and after the first DFPP‐session. Results In group 1, the loss of coagulation factors was significantly reduced as compared to group 2 for proteins with a molecular weight of >150 kDa: there was, respectively, an average decrease of 70% vs 31% for fibrinogen (P = 0.004), 66% vs 21% for factor V (P = 2.16e−07), 60% vs 32% for factor XI (P = 6.96e−06), 75% vs 17% for XIII‐antigen (P = 0.0002), and 47% vs 0% for VWF‐antigen(P = 0.02). The decrease in post‐session IgG was, on average, 45% in group 1 and 50% in group 2 (P = 0.13). Those results remained significant even when adjusted to the treated‐plasma volume and the pre‐DFPP factor values. Conclusion DFPP, using a CascadefloEC‐50W as a first‐filter, reduces efficiently IgGs similarly to PlasmafloOP‐08W but spares clotting factors.

show abstract

Double-Filtration Plasmapheresis Plus Low-Dose Anti-thymocyte Globulin and Tacrolimus in Asian Living-Donor Kidney Transplantation With Donor-Specific Anti-HLA Antibody

Cited by 4 publications

References 17 publications

Double filtration plasmapheresis combined with rituximab for donor‐specific antibody desensitization in haploidentical haematopoietic stem cell transplantation

Double filtration plasmapheresis combined with rituximab for donor‐specific antibody desensitization in haploidentical haematopoietic stem cell transplantation

A prospective, randomized, non-blinded, non-inferiority pilot study to assess the effect of low-dose anti-thymocyte globulin with low-dose tacrolimus and early steroid withdrawal on clinical outcomes in non-sensitized living-donor kidney recipients

How to improve clotting factors depletion in double‐filtration plasmapheresis

Contact Info

Product

Resources

About